Pete Giunta advises clients on intellectual property issues and litigates patent and technology disputes. His experience spans a wide array of technologies, including pharmaceuticals, biopharmaceuticals, biotechnology, medical devices, diagnostics, and electronics. Before studying law, Pete worked in several pharmaceutical and chemical companies, which helps him understand the issues companies face, and practice with a business-minded approach.
Pharmaceuticals and biologics are a major part of Pete's practice. He helps clients navigate the interface between patent and food and drug law. Generic, brand, biosimilar, and over-the-counter drug companies rely on his input in developing strategies for FDA filings, product launches, and post-marketing protection. His experience spans many therapeutic areas, including cancer, diabetes, HIV/AIDS, central nervous system, asthma, and microbial diseases. It also spans many dosage forms, including solid oral formulations, sterile injectables, inhaled dosage forms, topical agents, and ophthalmic solutions.
Pete has litigated numerous Hatch-Waxman cases through trial and appeal. He has had cases in federal district courts, the U.S. Court of Appeals for the Federal Circuit, and the International Trade Commission (ITC). Pete is registered to practice before the U.S. Patent & Trademark Office and counsels clients on Patent Trial and Appeal Board proceedings such as inter partes reviews (IPRs). In addition to litigation, Pete has represented clients in negotiations, mediations, and AAA and LCIA arbitrations in patent, trademark, and commercial disputes.
He likewise provides patent infringement, validity, and freedom-to-operate opinions, and advises on prosecution and licensing.
